American Well (NYSE:AMWL) Posts Quarterly Earnings Results

American Well (NYSE:AMWL) released its quarterly earnings data on Tuesday. The company reported ($0.67) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.11, FiscalAI reports. American Well had a negative return on equity of 30.12% and a negative net margin of 35.75%. The company had revenue of $48.99 million during the quarter, compared to the consensus estimate of $47.28 million.

Here are the key takeaways from American Well’s conference call:

• Q3 results exceeded guidance: Revenue was $49 million, $1 million above the high end of guidance, while adjusted EBITDA loss improved to $3.6 million from $12.7 million a year ago. Management cited stronger visit volumes and continued cost discipline.
• Amwell raised its full-year 2026 outlook to $204 million–$206 million in revenue and an adjusted EBITDA loss of $6.9 million–$7.9 million, versus the prior loss outlook of $12 million–$16 million. It expects fourth-quarter adjusted EBITDA to reach break-even to positive $1 million and operating cash flow to turn positive.
• The company reported strong growth in higher-value services, including a 41% year-over-year increase in virtual primary care visits and an 11% increase in AMG revenue per visit. Management said the improved member experience, activation tools and faster partner integration could support greater engagement and utilization.
• Amwell received a nonbinding letter of intent from the Department of Veterans Affairs to deploy its platform enterprise-wide across more than 9 million veterans, while negotiations continue on a longer-term direct contract with the Defense Health Agency. However, the VA agreement still requires a definitive contract, and timing and revenue contributions remain uncertain.
• Subscription revenue declined 22.5% year over year and 6.8% sequentially, reflecting previously disclosed customer churn, while total platform visits fell 30.5% year over year. Management expects less health-plan-related churn going forward but acknowledged some natural churn will continue in de-emphasized businesses.

American Well Price Performance

NYSE AMWL traded up $0.82 on Wednesday, reaching $13.56. The company had a trading volume of 71,180 shares, compared to its average volume of 100,865. The firm has a market cap of $224.42 million, a price-to-earnings ratio of -2.84 and a beta of 1.72. American Well has a fifty-two week low of $3.71 and a fifty-two week high of $15.16. The business has a 50 day moving average of $12.95 and a two-hundred day moving average of $8.99.

Trending Headlines about American Well

Here are the key news stories impacting American Well this week:

• Positive Sentiment: Third-quarter revenue was $48.99 million, above the cited $47.28 million estimate. The loss of $0.67 per share also narrowed from $1.74 a year earlier, and beat the $0.78 loss estimate cited by MarketBeat. Amwell Q3 2026 results
• Neutral Sentiment: Stifel Nicolaus lifted its price target from $11 to $12 but kept a Hold rating. The higher target is a modest positive, though it was still about 9.3% below the $13.24 share price referenced in the report. Stifel Nicolaus rating information
• Negative Sentiment: Consensus comparisons varied: Zacks said the $0.67 quarterly loss per share was slightly wider than its $0.66 estimate. The company also remains loss-making, a continuing risk for investors. Zacks Q3 earnings coverage

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on AMWL shares. Stifel Nicolaus lifted their target price on American Well from $11.00 to $12.00 and gave the stock a “hold” rating in a report on Wednesday. Wells Fargo & Company increased their target price on shares of American Well from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of American Well in a report on Wednesday, August 5th. Truist Financial set a $12.00 price target on shares of American Well and gave the company a “hold” rating in a research report on Thursday, August 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of American Well in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $11.30.

Insider Buying and Selling

In other news, insider Dmitry Zamansky sold 8,442 shares of the firm’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $13.00, for a total transaction of $109,746.00. Following the completion of the sale, the insider owned 224,178 shares of the company’s stock, valued at $2,914,314. This trade represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Phyllis Gotlib sold 6,677 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $13.00, for a total transaction of $86,801.00. Following the transaction, the insider owned 142,504 shares in the company, valued at $1,852,552. The trade was a 4.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 19,457 shares of company stock worth $248,519. 12.84% of the stock is owned by insiders.

About American Well

American Well, doing business as Amwell, is a digital healthcare company that provides technology and services for virtual care. Its platform connects patients with healthcare professionals through video and other digital channels, supporting services such as urgent care, behavioral health, primary care and specialty consultations.

Amwell primarily serves health systems, health plans, employers and other healthcare organizations. Its offerings include the Amwell Converge platform, which is designed to help organizations develop, manage and integrate digital care programs with existing clinical workflows and healthcare systems.

Founded in 2006 by brothers Ido and Roy Schoenberg, the company was formerly known as American Well and adopted the Amwell brand in 2020.